4 results
ObjectivesPrimary Efficacy Objective• To assess the sustained clinical effect of BM32 during 2 consecutive treatment years compared to placebo. The clinical effect of BM32 is evaluated by a combined Symptom-Medication-Score (SMS) which is recorded…
To determine the objective response rate (ORR) (complete response and partialresponse) of RAD001 10 mg po qd monotherapy in patients with advanced(unresectable or metastatic) pancreatic NET after the failure of cytotoxicchemotherapy.
To evaluate the ORR of belzutifan per RECIST 1.1 by blinded independent central review (BICR).
The main objectives for this study are: - To assess the safety and tolerability of the combination of pembrolizumab and lenvatinib and belzutifan.- To evaluate the confirmed objective response rate (ORR) per RECIST 1.1 as assessed by blinded…